secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPEL PHARMACEUTICALS INC (—)
CIK:        0001445499
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193125-23-277083
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Impel boosts interim CEO Paolillo salary to $600k, amends change-of-control MIP
-------------------------------------------------------------------------------

- Len Paolillo appointed interim CEO with base salary increased to $600,000 and increased MIP interest.
- CFO Michael Kalb receives one-time $30,000 salary advance, subject to repayment if he leaves before deal close or Dec 31, 2023.
- Amended MIP reallocates former CEO Adrian Adams' forfeited 0.85% net consideration interest to remaining participants.
- Compensation adjustments permitted via letter agreement with lender Oaktree Fund Administration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445499/000119312523277083/0001193125-23-277083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445499/000119312523277083/d367592d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer